Follow the 케이바이오랩스 stock price and the full insider trade history of the company, a listed issuer based in South Korea. Shares are quoted on KR KR, under the supervision of DART (FSS). Operating in the Health Care sector, 케이바이오랩스 has published 40 public disclosures. Market capitalisation: €22.6bn. The latest transaction was filed on 16 July 2026 (Other). Among the most active insiders: 미래아이앤지. All data is accessible without an account.
40
Insider Decl.
n/a
Thresholds
n/a
5 ops.
Buy Volume
n/a
22 ops.
Sell Volume
5Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,489 of 28,065 companies
36.2
score / 100
Value
55
Quality
18
FCF yld34%
Earn yld-14%
EV/EBITDA·
ROE·
Gross mgn14%
Net mgn-3.7%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
케이바이오랩스 is a company in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative solutions for the medical field.